NCT07648160 Contrast-enhanced CBCT With C-arm HyperSight Technology
| NCT ID | NCT07648160 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Health Network, Toronto |
| Condition | Advanced Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2026-06-24 |
| Primary Completion | 2027-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2026-06-24 with a primary completion date of 2027-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a single-arm prospective, feasibility study evaluating the intravenous contrast-enhanced cone beam computed tomography (IV CBCT) for image guidance during radiotherapy. Patients treated with SFRT will receive IV-contrast enhanced CT and fMRI before treatment for simulation purposes. Additionally, patients will receive mpMRI just before and IV-contrast enhanced CBCT during their second and last fraction of RT, in addition to the standard of care CBCT that is acquired for daily image-guided patient positioning. Patients will undergo both IV-contrast enhanced CBCT and treatment on the TrueBeam with HyperSight imaging capability. We hypothesize IV contrast enhanced CBCT is feasible, well-tolerated by patients and improves the visibility of the target.
Eligibility Criteria
Inclusion Criteria: * Primary biopsy-proven cancer * Planning to undergo spatially fractionated radiation therapy * Able to provide informed consent * Willingness to participate in follow-up * ECOG less than or equal to 3 * Normal creatinine (below 109mmol/L), normal eGF Exclusion Criteria: * Unable to understand/provide consent * History of allergic reaction to iodinated IV contrast dye (allergy to MR contrast is not an exclusion criteria) * Known renal disease * Single kidney * Kidney transplant * Dialysis * Contraindication to MRI
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07648160 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Advanced Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07648160 currently recruiting?
Yes, NCT07648160 is actively recruiting participants. Contact the research team at jelena.lukovic@uhn.ca for enrollment information.
Where is the NCT07648160 trial being conducted?
This trial is being conducted at Toronto, Canada.
Who is sponsoring the NCT07648160 clinical trial?
NCT07648160 is sponsored by University Health Network, Toronto. The trial plans to enroll 20 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.